Like all GLP-1 medications, GLP-1 works best over time and alongside healthy habits
Thus, we investigated GLP-1R expressions in the renal pelvis of rats with HF by real-time qRT-PCR and western blot analysis
Overall, results from the cardiovascular outcomes trials (CVOTs) completed for all marketed GLP-1 RAs in type 2 diabetes support a benefit in HF specifically in addition to the approved use in broad CVD risk reduction in people with type 2 diabetes (Sattar et al., 2021)
The FDA has warned against using these versions due to issues with incorrect ingredients, poor storage, or improper dosage
Weight loss is a marathon, not a sprint
Lancet Lond Engl 394:121130 Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
